InxMed Reveals Data from the P-Ib/II Study of Ifebemtinib Plus Garsorasib for Non-Small Cell Lung Cancer (NSCLC)
Shots:
- InxMed has reported results from the P-Ib/II study investigating ifebemtinib (oral) + garsorasib as a 1L treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients (n=33)
- The results, as of May 2024 in 31 evaluable patients, demonstrated a 90.3% ORR, 96.8% DCR as well as 28 PRs (26 were confimed) & 2 SDs with a consistent safety profile & grade 1 or 2 TRAEs plus grade 3 AEs. mDoR, PFS & OS evaluations are underway
- Ifebemtinib, a selective small molecule targeting focal adhesion kinase, was previously designated with the NMPA’s BTD and FDA’s FTD. The NMPA's NDA submission ia anticipated in early 2025
Ref: PR Newswire | Image: InxMed
Related News:- InxMed Signs a Clinical Trial Collaboration with Merck & Co for Patients with Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
